Document is current
Any future updates will be listed below
-
Authors
Yang-Jensen, Sune K. https://orcid.org/0000-0002-8157-6516
Choi, Béatrice S.-Y. https://orcid.org/0000-0001-8160-9448
Nägele, Nora S. https://orcid.org/0009-0007-4711-1954
Pærregaard, Simone I. https://orcid.org/0000-0001-6879-0529
Neven, Kobe https://orcid.org/0009-0008-0145-5978
Savickas, Vytautas
Gupta, Nazuk https://orcid.org/0009-0000-6012-2884
Modvig, Ida M.
Holm, Jacob B.
Kristiansen, Karsten https://orcid.org/0000-0002-6024-0917
Kissow, Hannelouise
Holst, Jens J. https://orcid.org/0000-0001-6853-3805
Hartmann, Bolette https://orcid.org/0000-0001-8509-2036
Jensen, Benjamin A. H. https://orcid.org/0000-0001-6991-0828
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (NNF21OC0066931)
Novo Nordisk Fonden (NNF20SA0064340)
Aage og Johanne Louis-Hansens Fond (24-2B-16713)
- License Information
-
More Information
Article History
Received: 1 July 2025
Accepted: 6 January 2026
First Online: 15 January 2026
Competing interests
: B.A.H.J., J.B.H., and K.K. are co-inventors of an issued patent (US and EU) related to McB and gut dysbiosis. B.A.H.J., S.K.Y.J., and B.S.Y.C. are co-inventors of a patent application related to McB’s potential in treating or preventing gastrointestinal barrier dysfunction. The remaining authors declare that there are no conflicts of interest.
